In a notable adjustment of its investment portfolio, American Century Companies Inc. has decreased its holdings in Bristol Myers Squibb Company by 3.8% during the third quarter. This decision was detailed in the recent Form 13F filing with the Securities and Exchange Commission. After the sale of 88,819 shares, American Century now owns 2,265,622 shares, which represents approximately 0.11% of the biopharmaceutical giant. This investment is valued at roughly $102 million based on the company’s recent market performance.
Shifts in Institutional Investments
Other institutional investors have also been active in modifying their positions regarding Bristol Myers Squibb. In the second quarter, Darwin Wealth Management LLC initiated a new position worth $25,000, while Harbor Capital Advisors Inc. significantly increased its stake by over 107%. After acquiring an additional 313 shares, their total ownership now stands at 605 shares valued at $27,000.
Total Investment Management Inc. and Twin Peaks Wealth Advisors LLC also entered the fray, with new investments amounting to approximately $38,000 and $40,000, respectively. Mark Sheptoff Financial Planning LLC made a substantial increase, raising its position by 233.3% to own 1,000 shares valued at $46,000. Collectively, institutional investors currently hold 76.41% of Bristol Myers Squibb’s stock.
Performance Metrics and Stock Analysis
On the trading front, Bristol Myers Squibb shares opened at $62.39, reflecting the company’s robust market presence. The biopharmaceutical company showcases a debt-to-equity ratio of 2.32 and maintains liquidity ratios with a quick ratio of 1.14 and a current ratio of 1.26. The market capitalization is approximately $127.05 billion, complemented by a P/E ratio of 18.08 and a PEG ratio of 0.18, indicating a relatively stable valuation.
Over the past year, the stock fluctuated between a low of $42.52 and a high of $63.33. The fifty-day and two-hundred-day moving averages sit at $57.13 and $50.67, respectively, suggesting a positive trend in performance.
Earnings Report Insights
Bristol Myers Squibb recently reported quarterly earnings, revealing earnings per share (EPS) of $1.26, which fell short of analysts’ expectations of $1.65 by $0.39. The company achieved a net margin of 14.64% and an impressive return on equity of 69.65%. Revenue for the quarter hit $12.50 billion, slightly surpassing the analyst consensus of $12.24 billion, and marking a 1.3% increase year-over-year.
Looking ahead, Bristol Myers Squibb has set its fiscal year 2026 guidance at an EPS range of 6.050 to 6.350, with analysts projecting an average EPS of 6.74 for the current year.
Dividend Growth and Shareholder Returns
The company also recently increased its quarterly dividend, paying out $0.63, which translates to an annualized dividend of $2.52 and a yield of 4.0%. This increase from the previous dividend of $0.62 demonstrates the company’s commitment to returning value to its shareholders. With a dividend payout ratio of 73.04%, Bristol Myers Squibb is positioned to maintain a balance between rewarding investors and reinvesting in growth opportunities.
Analyst Ratings and Market Outlook
Wall Street analysts have expressed varied opinions on Bristol Myers Squibb’s stock. UBS Group upgraded the stock from a “neutral” to a “buy” rating, raising the price target from $46.00 to $65.00. Similarly, Guggenheim reiterated a “buy” rating with an increased target price of $72.00, while Piper Sandler set an updated target of $75.00.
In contrast, Morgan Stanley issued an “underweight” rating with a target of $40.00. Overall, the consensus among analysts includes nine “buy” ratings, twelve “hold” ratings, and one “sell” rating, indicating a generally favorable outlook with a consensus price target of $60.71.
Conclusion
Bristol Myers Squibb continues to navigate a complex landscape of institutional investment and market performance. Recent modifications in shareholder positions, coupled with a solid earnings report and dividend growth, underscore its resilience and potential for future growth. As analysts remain divided yet largely optimistic about the company’s trajectory, Bristol Myers Squibb is poised to maintain its relevance in the biopharmaceutical sector. Investors should keep a watchful eye on upcoming developments, especially within its pipeline of innovative therapies.
- American Century Companies reduces its stake in Bristol Myers Squibb by 3.8%.
- Institutional investors hold over 76% of Bristol Myers Squibb stock.
- The company recently reported revenue surpassing analyst expectations.
- Bristol Myers Squibb increased its quarterly dividend, indicating strong shareholder returns.
- Analyst ratings show a mix of optimism and caution regarding future performance.
Read more → www.marketbeat.com